Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchPemivibartPemivibart (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
  Download Image
    
Share
  
Post
$0 $1,000 $2,000+ -25+% 0% 25% 50% Treatment cost (US$) Efficacy vs. cost for COVID-19 treatments Donidalorsen -151% >$2,000 Glenzocimab -60% >$2,000 PPIs -46% BMS mAbs -36% >$2,000 Acetaminophen -28% Lufotrelvir >$2,000 Trimodulin >$2,000 Losartan Sargramostim >$2,000 Cannabidiol Vitamin B9 Conv. Plasma $5,000 Remdesivir $3,120 Acebilustat >$2,000 Ibuprofen Aspirin Molnupiravir mutagenic/teratogenic Favipiravir Paxlovid Famotidine Amubarvimab/r.. Vitamin C NAC Vilobelimab $6,350 Sotrovimab $2,100 Colchicine Zinc Budesonide HCQ Probiotics Sleep Antiandro.. Metformin Nitric Oxide Azvudine Bebtelovimab Vitamin A Vitamin D Sunlight H. Peroxide Fluvox. H1RAs Exercise Curcumin Tixagevimab/c.. N. Sativa NaHCO₃ Casirivimab/i.. $2,100 Melatonin Ensovibep >$2,000 Bamlanivimab/e.. pH+ Quercetin Diet PVP-I Thermotherapy Ivermectin Regdanvimab $2,100 Lifestyle / free No prescription Prescription required High-cost Lowerrisk Higherrisk c19early.org September 2024 COVID-19 involves the interplay of 50+ host/viral proteins/factors, modulated by many treatments. 0.6% of 8,000+proposed treatments show efficacy with ≥3 studies.Protocols combine treatments, none are 100% effective.c19early analyzes over 4,700 studies for 95 treatments.
Home   Post   Share   @CovidAnalysis   OutcomesOutcomes   mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Casadevall, Choudhary, Günther, Leducq. Recent:
Wang
Casadevall. Submit updates/corrections. Summary.
PemivibartAll
Aug 13
 Wang et al., bioRxiv, doi:10.1101/2024.08.12.607496 Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages
In Vitro study showing pemivibart has reduced neutralizing activity against recent SARS-CoV-2 JN.1 sublineages, particularly KP.3.1.1 which had a 32.7-fold higher IC50 compared to the original JN.1. Structural analyses suggest the Q493E m..
Aug 11
 Focosi, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268 Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date.
Aug 8
 Casadevall et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408 Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship
Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod..
Mar 22
 Invivyd Press Release Invivyd announces FDA authorization for emergency use of Pemgarda™ (formerly VYD222) for pre-exposure prophylaxis (PrEP) of COVID-19
RCT 623 patients reporting immunobridging results from cohort A with 306 immunocompromised patients. Immunobridging estimates efficacy from the relationship between serum virus neutralizing antibody titers and clinical efficacy demonstrat..
Nov 27
2023
 Mahoney et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad500.1200 Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
Phase 1 RCT of monoclonal antibody VYD222 (pemivibart) in 12 healthy adults, showing no serious adverse events or infusion-related reactions through 14 days with 1500mg and through 2 days with 2500mg.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
@CovidAnalysis
FAQ
Public domain CC0 1.0